Lonza Backs Guidance Despite Soft Start to Year
Provided by
Dow Jones
By David Sachs
Lonza said its performance over the first quarter was soft but that it expects the first half to move in line with last year, and backed its full-year guidance.
The Swiss pharmaceutical company said Tuesday that it still expects flat sales growth at constant exchange rates for the year and core earnings before interest, taxes, depreciation and amortization margin in the high 20s.
Sales for the second half year are expected to be solid, reflecting the time of batch releases.
It didn't provide any actual figures for the first quarter.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 14, 2024 01:38 ET (05:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
13 Charts On the Market’s Q2 Turnaround
-
10 Top-Performing Dividend Stocks of Q2 2024
-
Markets Brief: US Jobs Report In View as Q3 Begins
-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Energy: OPEC Continues to Operate From a Position of Weakness With Production Cuts Extension
-
Communication Services: Online Advertising Remains Strong, but Growth Will Likely Decelerate
-
3 Stocks to Buy This Summer While They’re Seriously Undervalued
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded